Oligodendroglial Lineage Cells in Thyroid Hormone-Deprived Conditions

• Published in: Stem cells international Vol. 2019; no. 2019; pp. 1 - 13
• Main Authors: Kim, Min Joung, Petratos, Steven
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2019; Hindawi; John Wiley & Sons, Inc; Hindawi Limited; Wiley
• Subjects: Acids; Brain; Cell adhesion & migration; Cell differentiation; Central nervous system; Communication; Differentiation (biology); Endocrinology; Genotype & phenotype; Glial cells; Glial stem cells; Glycoproteins; Homeostasis; Hormones; Intellectual disabilities; Intracellular; Intracellular signalling; Maturation; Metabolism; Multiple sclerosis; Mutation; Myelination; Nervous system; Neurodegeneration; Neuronal-glial interactions; Neurons; Oligodendrocytes; Physiological aspects; Physiology; Precursors; Propagation; Proteins; Review; Thyroid; Thyroid gland; Triiodothyronine
• ISSN: 1687-966X; 1687-9678; 1687-9678
• DOI: 10.1155/2019/5496891

Oligodendrocytes are supporting glial cells that ensure the metabolism and homeostasis of neurons with specific synaptic axoglial interactions in the central nervous system. These require key myelinating glial trophic signals important for growth and metabolism. Thyroid hormone (TH) is one such trophic signal that regulates oligodendrocyte maturation, myelination, and oligodendroglial synaptic dynamics via either genomic or nongenomic pathways. The intracellular and extracellular transport of TH is facilitated by a specific transmembrane transporter known as the monocarboxylate transporter 8 (MCT8). Dysfunction of the MCT8 due to mutation, inhibition, or downregulation during brain development leads to inherited hypomyelination, which manifests as psychomotor retardation in the X-linked inherited Allan-Herndon-Dudley syndrome (AHDS). In particular, oligodendroglial-specific MCT8 deficiency may restrict the intracellular T3 availability, culminating in deficient metabolic communication between the oligodendrocytes and the neurons they ensheath, potentially promulgating neurodegenerative adult diseases such as multiple sclerosis (MS). Based on the therapeutic effects exhibited by TH in various preclinical studies, particularly related to its remyelinating potential, TH has now entered the initial stages of a clinical trial to test the therapeutic efficacy in relapsing-remitting MS patients (NCT02506751). However, TH analogs, such as DITPA or Triac, may well serve as future therapeutic options to rescue mature oligodendrocytes and/or promote oligodendrocyte precursor cell differentiation in an environment of MCT8 deficiency within the CNS. This review outlines the therapeutic strategies to overcome the differentiation blockade of oligodendrocyte precursors and maintain mature axoglial interactions in TH-deprived conditions.